FBB
REGN icon

Fulton Breakefield Broenniman’s Regeneron Pharmaceuticals REGN Stock Holding History

Fulton Breakefield Broenniman’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-216
Closed -$227K – 199
2024
Q3 		$227K Hold
216
– – 0.02% 172
2024
Q2 		$227K Hold
216
– – 0.02% 173
2024
Q1 		$208K Buy
+216
New +$205K 0.02% 176
2020
Q3 		– Sell
-440
Closed -$274K – 178
2020
Q2 		$274K Buy
440
+4
+0.9% +$2.27K 0.03% 144
2020
Q1 		$213K Buy
+436
New +$180K 0.03% 144

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fulton Breakefield Broenniman's REGN Position: Q4 2024 in Review

Fulton Breakefield Broenniman sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 216 shares — an estimated $227K sold.

Fulton Breakefield Broenniman first reported a position in REGN in Q1 2020 and held it in 5 quarters. The position peaked at $274K in Q2 2020. 1,317 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • Fulton Breakefield Broenniman reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Fulton Breakefield Broenniman sold 216 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $227K.
  • Fulton Breakefield Broenniman first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 5 quarters.
  • Fulton Breakefield Broenniman's Regeneron Pharmaceuticals position peaked at $274K in Q2 2020.
  • 1,317 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Fulton Breakefield Broenniman's 13F filing for Q4 2024, filed 23 Jan 2025.